Dr. Jonathan R. Strosberg on the NETTER-1 Trial and its Impact on Patients With Midgut NETs

During a Case-Based Roundtable® event, Sagar D. Sardesai, MD, moderated a discussion on using antibody-drug conjugates and managing their toxicities in patients with metastatic breast cancer.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

The sponsor is preparing a phase 2 study to evaluate namodenoson in this patient population.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

In an interview with Targeted Oncology, Jeffrey Wong, MD, discussed the potential and future directions of Cu 64 anti-CEA M5A as a PET imaging agent for advanced rectal cancer.

Evidence suggests that extranodal extension on radiological imaging is a negative prognostic factor in head and neck cancer, but diagnostic criteria and terminology have been unclear.